Boron chemicals in diagnosis and therapeutics

Future Medicinal Chemistry

Volumn 5, Issue 6, 2013, Pages 653-676

  Das, Bhaskar C ^a,b,c   Thapa, Pritam ^a   Karki, Radha ^a   Schinke, Caroline ^d   Das, Sasmita ^a   Kambhampati, Suman ^a,b   Banerjee, Sushanta K ^a,b   Van Veldhuizen, Peter ^a,b   Verma, Amit ^d   Weiss, Louis M ^d   Evans, Todd ^c  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 3,5 BIS(4 BORONIC ACID BENZYLIDENE) 1 METHYLPIPERIDIN 4 ONE; 4 BORONOPHENYLALANINE; ACETANILIDE DERIVATIVE; AFIMOXIFENE; AN 0128; AN 2718; AN 2728; ANGIOGENESIS INHIBITOR; AUTOTAXIN; BE 360; BOCEPREVIR; BOROCAPTATE; BORON DERIVATIVE; BORTEZOMIB; CHALCONE DERIVATIVE; COMBRETASTATIN A4; DANOPREVIR; DELANZOMIB; DIPYRROMETHENE BORON DIFLUORIDE; DOCETAXEL; DUTOGLIPTIN; FLOVAGATRAN; GB 10; GN 26361; GSK 2251052; HA 130; HISTONE DEACETYLASE INHIBITOR; ICI 75 188; ICI 78 911; IXAZOMIB; IXAZOMIB CITRATE; N (2 PYRAZINECARBONYL)LEUCINE(2 NAPHTHYL)ALANINE LEUCINE BORONIC ACID; PHENOXYACETANILIDE DERIVATIVE; PROTEASOME INHIBITOR; SCYX 7158; TALABOSTAT; TAVABOROLE; TELAPREVIR; TGN 167; TP 110; TRI 50 C; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIFUNGAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; BREAST CANCER; BREAST CARCINOMA; CHEMICAL ANALYSIS; CHEMICAL COMPOSITION; CHEMICAL LABELING; COLON CARCINOMA; DIAGNOSTIC IMAGING; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG POTENCY; ENZYME INHIBITION; FLUORESCENCE; HEMATOLOGIC MALIGNANCY; HUMAN; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; LYMPHOMA; MANTLE CELL LYMPHOMA; MOLECULAR PROBE; MULTIPLE MYELOMA; NEUTRON CAPTURE THERAPY; NONHODGKIN LYMPHOMA; NONHUMAN; ONYCHOMYCOSIS; OSTEOPOROSIS; PANCREAS CARCINOMA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEOMICS; REVIEW; SOLID TUMOR;

BORON COMPOUNDS; BORON NEUTRON CAPTURE THERAPY; BORONIC ACIDS; FLUORESCENT DYES; HUMANS; LYMPHOMA, NON-HODGKIN; MULTIPLE MYELOMA; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEASOME INHIBITORS; PYRAZINES; REACTIVE OXYGEN SPECIES;

EID: 84876850505     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.13.38     Document Type: Review

References (150)

1. Hunt CD. Dietary boron: Progress in establishing essential roles in human physiology. J. Trace Elem. Med. Biol. 26(2-3), 157-160 (2012
2. Benderdour M, Bui-Van T, Dicko A, Belleville F. In vivo and in vitro effects of boron and boronated compounds. J. Trace Elem. Med. Biol. 12(1), 2-7 (1998
3. Rezanka T, Sigler K. Biologically active compounds of semi-metals. Phytochemistry 69(3), 585-606 (2008
4. Baker SJ, Ding CZ, Akama T, Zhang YK, Hernandez V, Xia Y. Therapeutic potential of boron-containing compounds. Future Med. Chem. 1(7), 1275-1288 (2009
5. Ciani L, Ristori S. Boron as a platform for new drug design. Expert Opin. Drug Discov. 7(11), 1017-1027 (2012
6. Cid J, Carbó JJ, Fernández E. Disclosing the structure/activity correlation in trivalent boron-containing compounds: A tendency map. Chem. Eur. J. 18(40), 12794-12802 (2012
7. Brown HC, Malhotra SV, Ramachandran PV. Organoboranes for synthesis 17. Generality of hydroboration-Tmination for the conversion of terpenes into enantiomerically pure terpenylamines. Their utility for gas chromatographic analysis of chiral carboxylic acids. Tetrahedron Asym. 7, 3527 (1996
8. Yang W, Gao X, Wang B. Boronic acid compounds as potential pharmaceutical agents. Med. Res. Rev. 23(3), 346-368 (2003
9. Klotz JH, Moss JI, Zhao R, Davis LR, Patterson RS. Oral toxicity of boric acid and other boron compounds to immature cat fleas (Siphonaptera: Pulicidae). J. Econ. Entomol. 87(6), 1534-1536 (1994
10. Smedskjaer MM, Mauro JC, Youngman RE, Hogue CL, Potuzak M, Yue Y. Topological principles of borosilicate glass chemistry. J. Phys. Chem. B. 115(44), 12930-12946 (2011
11. Richold M. Boron exposure from consumer products. Biol. Trace Elem. Res. 66(1-3), 121-129 (1998
12. Lewis DR. Dopant materials used in the microelectronics industry. Occup. Med. 1(1), 35-47 (1986
13. Genin E, Reboud-Ravaux M, Vidal J. Proteasome inhibitors: Recent advances and new perspectives in medicinal chemistry. Curr. Top. Med. Chem. 10(3), 232-256 (2010
14. Tashiro E, Imoto M. Target identification of bioactive compounds. Bioorg. Med. Chem. 20(6), 1910-1921 (2012
15. Ojida A, Sakamoto T, Inoue MA, Fujishima SH, Lippens G, Hamachi I. Fluorescent BODIPY-based Zn (II) complex as a molecular probe for selective detection of neurofibrillary tangles in the brains of Alzheimer's disease patients. J. Am. Chem. Soc. 131(18), 6543-6548 (2009
16. Cummins TD, Higdon AN, Kramer PA et al. Utilization of fluorescent probes for the quantification and identification of subcellular proteomes and biological processes regulated by lipid peroxidation products. Free. Radic. Biol. Med. doi:10.1016/j. freeradbiomed.2012.08.014 (2012) (Epub ahead of print
17. Greenbaum D, Baruch A, Hayrapetian L et al. Chemical approaches for functionally probing the proteome. Mol. Cell Proteomics. 1(1), 60-68 (2002
18. Greenbaum D, Medzihradszky KF, Burlingame A, Bogyo M. Epoxide electrophiles as activity-dependent cysteine protease profiling and discovery tools. Chem. Biol. 7(8), 569-581 (2000
19. Takamura-Enya T, Ishii R. BODIPY-modified 2́-deoxyguanosine as a novel tool to detect DNA damages. Bioorg. Med. Chem. Lett. 21(14), 4206-4209 (2011
20. Shin SB, Almeida RD, Gerona-Navarro G, Bracken C, Jaffrey SR. Assembling ligands in situ using bioorthogonal boronate ester synthesis. Chem. Biol. 17(11), 1171-1176 (2010
21. Fossey JS, D'Hooge F, van den Elsen JM et al. The development of boronic acids as sensors and separation tools. Chem. Rec. 12, 464-478 (2012
22. Weith HL, Wiebers JL, Gilham PT. Synthesis of cellulose derivatives containing the dihydroxyboryl group and study of their capacity to form specific complexes with sugars and nucleic acid components. Biochemistry 9(22), 4396-4401 (1970
23. Li Y, Pfuller U, Larsson EL, Jungvid H, Galaev IY, Mattiasson B. Separation of mistletoe lectins based on the degree of glycosylation using boronate affinity chromatography. J. Chromatogr. A 925(1-2), 115-121 (2001
24. Jerkovic B, Kung HC, Bolton PH. Purification of thymine glycol DNA and nucleosides by use of boronate chromatography. Anal. Biochem. 255(1), 90-94 (1998
25. Zembower DE, Neudauer CL, Wick MJ, Ames MM. Peptide boronic acids. Versatile synthetic ligands for affinity chromatography of serine proteinases. Int. J. Pept. Protein Res. 47(5), 405-413 (1996
26. Willey DG, Rosenthal MA, Caldwell S. Glycosylated haemoglobin and plasma glycoprotein assays by affinity chromatography. Diabetologia 27(1), 56-58 (1984
27. Liu Y, Fiskum G, Schubert D. Generation of reactive oxygen species by the mitochondrial electron transport chain. J. Neurochem. 80(5), 780-787 (2002
28. Turrens JF. Mitochondrial formation of reactive oxygen species. J. Physiol. 552(Pt 2), 335-344 (2003
29. Chen Q, Vazquez EJ, Moghaddas S, Hoppel CL, Lesnefsky EJ. Production of reactive oxygen species by mitochondria: Central role of complex III. J. Biol. Chem. 278(38), 36027-36031 (2003
30. Babior BM. The respiratory burst of phagocytes. J. Clin. Invest. 73(3), 599-601 (1984
31. Dröge W. Free radicals in the physiological control of cell function. Physiol. Rev. 82(1), 47-95 (2002
32. Zangar RC, Davydov DR, Verma S. Mechanisms that regulate production of reactive oxygen species by cytochrome P450. Toxicol. Appl. Pharmacol. 199(3), 316-331 (2004
33. Avery SV. Molecular targets of oxidative stress. Biochem. J. 434(2), 201-210 (2011
34. Petros JA, Baumann AK, Ruiz-Pesini E et al. mtDNA mutations increase tumorigenicity in prostate cancer. Proc. Natl Acad. Sci. USA 102(3), 719-724 (2005
35. Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB. Oxidative stress, inflammation, and cancer: How are they linked? Free Radic. Biol. Med. 49(11), 1603-1616 (2010
36. Waris G, Ahsan H. Reactive oxygen species: Role in the development of cancer and various chronic conditions. J. Carcinog. 5, 14 (2006
37. Luanpitpong S, Talbott SJ, Rojanasakul Y et al. Regulation of lung cancer cell migration and invasion by reactive oxygen species and caveolin-1. J. Biol. Chem. 285(50), 38832-38840 (2010
38. Emerit J, Edeas M, Bricaire F. Neurodegenerative diseases and oxidative stress. Biomed Pharmacother. 58 (1), 39-46 (2004
39. Christen Y. Oxidative stress and Alzheimer disease. Am. J. Clin. Nutr. 71(2), 621S-629S (2000
40. Sugamura K, Keaney JF Jr. Reactive oxygen species in cardiovascular disease. Free Radic. Biol. Med. 51(5), 978-992 (2011
41. Fearon IM, Faux SP. Oxidative stress and cardiovascular disease: Novel tools give (free) radical insight. J. Mol. Cell Cardiol. 47(3), 372-381 (2009
42. Papaharalambus CA, Griendling KK. Basic mechanisms of oxidative stress and reactive oxygen species in cardiovascular injury. Trends Cardiovasc. Med. 17(2), 48-54 (2007
43. Stadtman ER. Role of oxidant species in aging. Curr. Med. Chem. 11(9), 1105-1112 (2004
44. Kregel KC, Zhang HJ. An integrated view of oxidative stress in aging: Basic mechanisms, functional effects, and pathological considerations. Am. J. Physiol. Regul. Integr. Comp. Physiol. 292(1), R18-R36 (2007
45. Long LH, Evans PJ, Halliwell B. Hydrogen peroxide in human urine: Implications for antioxidant defense and redox regulation. Biochem. Biophys. Res. Commun. 262(3), 605-609 (1999
46. Banerjee D, Madhusoodanan UK, Nayak S, Jacob J. Urinary hydrogen peroxide: A probable marker of oxidative stress in malignancy. Clin. Chim. Acta 334(1-2), 205- 209 (2003
47. Forman HJ, Maiorino M, Ursini F. Signaling functions of reactive oxygen species. Biochemistry 49(5), 835-842 (2010
48. Chang MC, Pralle A, Isacoff EY, Chang CJ. A selective, cell-permeable optical probe for hydrogen peroxide in living cells. J. Am. Chem. Soc. 126(47), 15392-15393 (2004
49. Miller EW, Albers AE, Pralle A, Isacoff EY, Chang CJ. Boronate-based fluorescent probes for imaging cellular hydrogen peroxide. J. Am. Chem. Soc. 127(47), 16652-16659 (2005
50. Miller EW, Tulyathan O, Isacoff EY, Chang CJ. Molecular imaging of hydrogen peroxide produced for cell signaling. Nat. Chem. Biol. 3(5), 263-267 (2007
51. Dickinson BC, Huynh C, Chang CJ. A palette of fluorescent probes with varying emission colors for imaging hydrogen peroxide signaling in living cells. J. Am. Chem. Soc. 132(16), 5906-5915 (2010
52. Van de Bittner GC, Dubikovskaya EA, Bertozzi CR, Chang CJ. In vivo imaging of hydrogen peroxide production in a murine tumor model with a chemoselective bioluminescent reporter. Proc. Natl Acad. Sci. USA 107(50), 21316-21321 (2010
53. Boss DS, Olmos RV, Sinaasappel M, Beijnen JH, Schellens JH. Application of PET/CT in the development of novel anticancer drugs. Oncologist 13(1), 25-38 (2008
54. Ting R, Adam MJ, Ruth TJ, Perrin DM. Arylfluoroborates and alkylfluorosilicates as potential PET imaging agents: High-yielding aqueous biomolecular 18F-labeling. J. Am. Chem. Soc. 127(38), 13094-13095 (2005
55. Ting R, Harwig C, auf dem Keller U et al. Toward [18F]-labeled aryltrifluoroborate radiotracers: In vivo positron emission tomography imaging of stable aryltrifluoroborate clearance in mice. J. Am. Chem. Soc. 130(36), 12045-12055 (2008
56. auf dem Keller U, Bellac CL, Li Y et al. Novel matrix metalloproteinase inhibitor [18F] marimastat-Tryltrifluoroborate as a probe for in vivo positron emission tomography imaging in cancer. Cancer Res. 70(19), 7562-7569 (2010
57. Halo TL, Appelbaum J, Hobert EM, Balkin DM, Schepartz A. Selective recognition of protein tetraserine motifs with a cell-permeable, pro-fluorescent bis-boronic acid. J. Am Chem Soc. 131(2), 438-439 (2009
58. Kane RC, Bross PF, Farrell AT, Pazdur R. Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist 8(6), 508-513 (2003
59. San Miguel J, Bladé J, Boccadoro M et al. A practical update on the use of bortezomib in the management of multiple myeloma. Oncologist 11(1), 51-61 (2006
60. Gollob JA, Sciambi CJ. Decitabine up-regulates S100A2 expression and synergizes with IFN-gamma to kill uveal melanoma cells. Clin. Cancer Res. 13(17), 5219-5225 (2007
61. Codony-Servat J, Tapia MA, Bosch M et al. Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells. Mol. Cancer Ther. 5(3), 665-675 (2006
62. Schmid P, Kühnhardt D, Kiewe P et al. A Phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines. Ann. Oncol. 19(5), 871-876 (2008
63. Schenkein DP. Preclinical data with bortezomib in lung cancer. Clin. Lung Cancer. 7(Suppl 2), S49-S55 (2005
64. Davies AM, Lara PN Jr, Mack PC, Gandara DR. Incorporating bortezomib into the treatment of lung cancer. Clin. Cancer Res. 13(15Pt 2), s4647-s4651 (2007
65. Voutsadakis IA, Patrikidou A, Tsapakidis K et al. Additive inhibition of colorectal cancer cell lines by aspirin and bortezomib. Int. J. Colorectal Dis. 25(7), 795-804 (2010
66. Cusack JC Jr, Liu R, Houston M et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: Implications for systemic nuclear factor-kappaB inhibition. Cancer Res. 61(9), 3535-3540 (2001
67. Papandreou CN, Logothetis CJ. Bortezomib as a potential treatment for prostate cancer. Cancer Res. 64(15), 5036-5043 (2004
68. Hu W, Zheng RR, Cui HX, Yue D, Wang Y, Jiang YH. Effects of bortezomib in sensitizing human prostate cancer cell lines to NK-mediated cytotoxicity. Asian J. Androl. 14(5), 695-702 (2012
69. Nawrocki ST, Carew JS, Pino MS et al. bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis. Cancer Res. 65(24), 11658-11666 (2005
70. Adams J, Palombella VJ, Sausville EA et al. Proteasome inhibitors: A novel class of potent and effective antitumor agents. Cancer Res. 59(11), 2615-2622 (1999
71. Adams J. The proteasome: A suitable antineoplastic target. Nat. Rev. Cancer. 4(5), 349-360 (2004
72. Sartore-Bianchi A, Gasparri F, Galvani A et al. bortezomib inhibits nuclear factor-kB dependent survival and has potent in vivo activity in mesothelioma. Clin. Cancer Res. 13(19), 5942-5951 (2007
73. Landowski TH, Megli CJ, Nullmeyer KD, Lynch RM, Dorr RT. Mitochondrial-mediated disregulation of Ca2+ is a critical determinant of Velcade (PS-341/bortezomib) cytotoxicity in myeloma cell lines. Cancer Res. 65(9), 3828-3836 (2005
74. Cunningham CC. Talabostat. Expert Opin. Investig. Drugs. 16(9), 1459-1465 (2007
75. Eager RM, Cunningham CC, Senzer N et al. Phase II trial of talabostat and docetaxel in advanced non-small cell lung cancer. Clin. Oncol. (R. Coll. Radiol.) 21(6), 464-472 (2009
76. Orlowski RZ, Kuhn DJ. Proteasome inhibitors in cancer therapy: Lessons from the first decade. Clin Cancer Res. 14(6), 1649-1657 (2008
77. Richardson PG, Sonneveld P, Schuster MW et al. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: Impact of a dose-modification guideline. Br. J. Haematol. 144(6), 895-903 (2009
78. Dick LR, Fleming PE. Building on bortezomib: Second-generation proteasome inhibitors as anti-cancer therapy. Drug Discov. Today 15(5-6), 243-249 (2010
79. Kupperman E, Lee EC, Cao Y et al. Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res. 70(5), 1970-1980 (2010
80. Piva R, Ruggeri B, Williams M et al. CEP- 18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib. Blood 111(5), 2765-2775 (2008
81. Zhu Y, Yao S, Xu B et al. Design, synthesis and biological evaluation of tripeptide boronic acid proteasome inhibitors. Bioorg. Med. Chem. 17(19), 6851-6861 (2009
82. Watanabe T, Momose I, Abe M et al. Synthesis of boronic acid derivatives of tyropeptin: Proteasome inhibitors. Bioorg. Med. Chem. Lett. 19(8), 2343-2345 (2009
83. Achanta G, Modzelewska A, Feng L, Khan SR, Huang P. A boronic-chalcone derivative exhibits potent anticancer activity through inhibition of the proteasome. Mol. Pharmacol. 70(1), 426-433 (2006
84. Jiang Q, Zhong Q, Zhang Q, Zheng S, Wang G. Boron-based 4-hydroxytamoxifen bioisosteres for treatment of de novo tamoxifen resistant breast cancer. ACS Med. Chem Lett. 3(5), 392-396 (2012
85. Sambucetti LC, Fischer DD, Zabludoff S et al. Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects. J. Biol. Chem. 274(49), 34940-34947 (1999
86. Matsuzaki Y, Sowa Y, Hirose T, Yokota T, Sakai T. Histone deacetylase inhibitors -promising agents for 'gene-regulating chemoprevention' and 'molecular-targeting prevention' of cancer. Environ. Health Prev. Med. 8(5), 157-160 (2003
87. Suzuki N, Suzuki T, Ota Y et al. Design, synthesis, and biological activity of boronic acid-based histone deacetylase inhibitors. J. Med. Chem. 52(9), 2909-2922 (2009
88. Tanaka M, Okudaira S, Kishi Y et al. Autotaxin stabilizes blood vessels and is required for embryonic vasculature by producing lysophosphatidic acid. J. Biol. Chem. 281(35), 25822-25830 (2006
89. van Meeteren LA, Ruurs P, Stortelers C et al. Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development. Mol. Cell Biol. 26(13), 5015-5022 (2006
90. Mills GB, Moolenaar WH. The emerging role of lysophosphatidic acid in cancer. Nat. Rev. Cancer. 3(8), 582-591 (2003
91. Albers HM, Dong A, van Meeteren LA et al. Boronic acid-based inhibitor of autotaxin reveals rapid turnover of LPA in the circulation. Proc. Natl Acad. Sci. USA 107(16), 7257-7262 (2010
92. Nakamura H, Kuroda H, Saito H et al. Synthesis and biological evaluation of boronic acid containing cis-stilbenes as apoptotic tubulin polymerization inhibitors. ChemMedChem 1(7), 729-740 (2006
93. Das BC, Tang XY, Rogler P, Evans T. Design and synthesis of 3,5-disubstituted boron-containing 1,2,4-oxadiazoles as potential combrestatin A-4(CA-4) analogs. Tetrahedron Lett. 53(31), 3947-3950 (2012
94. Shimizu K, Maruyama M, Yasui Y, Minegishi H, Ban HS, Nakamura H. Boron-containing phenoxyacetanilide derivatives as hypoxia-inducible factor (HIF)-1a inhibitors. Bioorg. Med. Chem. Lett. 20(4), 1453-1456, (2010
95. Peng X, Gandhi V. ROS-Tctivated anticancer prodrugs: A new strategy for tumor-specific damage. Ther. Deliv. 3(7), 823-833 (2012
96. Kuang Y, Balakrishnan K, Gandhi V, Peng X. Hydrogen peroxide inducible DNA cross-linking agents: Targeted anticancer prodrugs. J. Am. Chem. Soc. 133(48), 19278-19281 (2011
97. Cao S, Wang Y, Peng X. ROS-inducible DNA cross-linking agent as a new anticancer prodrug building block. Chem. Eur. J. 18(13), 3850-3854 (2012
98. Ogawa T, Ohta K, Yoshimi T et al. m-Carborane bisphenol structure as a pharmacophore for selective estrogen receptor modulators. Bioorg. Med. Chem. Lett. 16(15), 3943-3946 (2006
99. Hirata M, Inada M, Matsumoto C et al. A novel carborane analog, BE360, with a carbon-containing polyhedral boron-cluster is a new selective estrogen receptor modulator for bone. Biochem. Biophys. Res. Commun. 380(2), 218-222 (2009
100. LeBeau AM, Singh P, Isaacs JT, Denmeade SR. Potent and selective peptidyl boronic acid inhibitors of the serine protease prostate-specific antigen. Chem. Biol. 15(7), 665-674 (2008
101. Soloway AH, Tjarks W, Barnum BA et al. The chemistry of neutron capture therapy. Chem. Rev. 98(4), 1515-1562 (1998
102. Barth RF, Vicente MG, Harling OK et al. Current status of boron neutron capture therapy of high grade gliomas and recurrent head and neck cancer. Radiat. Oncol. 29(7), 146 (2012
103. Yasui L, Kroc T, Gladden S, Andorf C, Bux S, Hosmane N. Boron neutron capture in prostate cancer cells. Appl. Radiat. Isot. 70(1), 6-12 (2012
104. Hawthorne MF, Lee MW. A critical assessment of boron target compounds for boron neutron capture therapy. J. Neurooncol. 62(1-2), 33-45 (2003
105. Calabrese G, Nesnas JJ, Barbu E, Fatouros D, Tsibouklis J. The formulation of polyhedral boranes for the boron neutron capture therapy of cancer. Drug Discov. Today 17(3-4), 153-159 (2012
106. Hasabelnaby S, Goudah A, Agarwal HK, Abd Alla MS, Tjarks W. Synthesis, chemical and enzymatic hydrolysis, and aqueous solubility of amino acid ester prodrugs of 3-carboranyl thymidine analogs for boron neutron capture therapy of brain tumors. Eur. J. Med. Chem. 55, 325-334 (2012
107. Kawabata S, Yang W, Barth RF et al. Convection enhanced delivery of carboranylporphyrins for neutron capture therapy of brain tumors. J. Neurooncol. 103(2), 175-185 (2011
108. Adams DM, Ji W, Barth RF, Tjarks W. Comparative in vitro evaluation of dequalinium B, a new boron carrier for neutron capture therapy (NCT). Anticancer Res. 20(5B), 3395-3402 (2000
109. Kabalka GW, Shaikh AL, Barth RF et al. Boronated unnatural cyclic amino acids as potential delivery agents for neutron capture therapy. Appl. Radiat. Isot. 69(12), 1778-1781 (2011
110. Golberg D, Bando Y, Huang Y et al. Boron nitride nanotubes and nanosheets. ACS Nano. 4(6), 2979-2993 (2010
111. Ciofani G, Raff V, Menciassi A, Cuschieri A. Folate functionalized boron nitride nanotubes and their selective uptake by glioblastoma multiforme cells: Implications for their use as boron carriers in clinical boron neutron capture therapy. Nanoscale Res. Lett. 4(2), 113-121 (2009
112. Raffa V, Riggio C, Smith MW, Jordan KC, Cao W, Cuschieri A. BNNT-mediated rreversible electroporation: Its potential on cancer cells. Technol. Cancer Res. Treat. 11(5), 459-465 (2012
113. Memon MI, Memon MA. Hepatitis C: An epidemiological review. J. Viral Hepat. 9(2), 84-100 (2002
114. Yao F, Terrault N. Hepatitis C and hepatocellular carcinoma. Curr. Treat. Options Oncol. 2(6), 473-483 (2001
115. Zoulim F, Chevallier M, Maynard M, Trepo C. Clinical consequences of hepatitis C virus infection. Rev. Med. Virol. 13(1), 57-68 (2003
116. Kwong AD, Kim JL, Rao G, Lipovsek D, Raybuck SA. Hepatitis C virus NS3/4A protease. Antiviral Res. 40(1-2), 1-18 (1998
117. Bartenschlager R. The NS3/4A proteinase of the hepatitis C virus: Unraveling structure and function of an unusual enzyme and a prime target for antiviral therapy. J. Viral Hepat. 6(3), 165-181 (1999
118. Li X, Zhang YK, Liu Y et al. Novel macrocyclic HCV NS3 protease inhibitors derived from a-Tmino cyclic boronates. Bioorg. Med. Chem. Lett. 20(19), 5695-5700 (2010
119. Deutsch M, Papatheodoridis GV. Danoprevir, a small-molecule NS3/4A protease inhibitor for the potential oral treatment of HCV infection. Curr. Opin. Investig. Drugs. 11(8), 951-963 (2010
120. Seiwert SD, Andrews SW, Jiang Y et al. Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227). Antimicrob. Agents Chemother. 52(12), 4432-4441 (2008
121. Li X, Zhang YK, Liu Y et al. Synthesis of new acylsulfamoyl benzoxaboroles as potent inhibitors of HCV NS3 protease. Bioorg. Med. Chem. Lett. 20(24), 7493-7497 (2010
122. Li X, Zhang YK, Liu Y et al. Synthesis and evaluation of novel alpha-Tmino cyclic boronates as inhibitors of HCV NS3 protease. Bioorg. Med. Chem. Lett. 20(12), 3550-3556 (2010
123. Venkatraman S, Wu W, Prongay A, Girijavallabhan V, George Njoroge F. Potent inhibitors of HCV-NS3 protease derived from boronic acids. Bioorg. Med. Chem. Lett. 19(1), 180-183 (2009
124. Ramkumar K, Tambov KV, Gundla R et al. Discovery of 3-Tcetyl-4-hydroxy-2- pyranone derivatives and their difluoridoborate complexes as a novel class of HIV-1 integrase inhibitors. Bioorg. Med. Chem. 16(19), 8988-8998 (2008
125. Baker SJ, Zhang YK, Akama T et al. Discovery of a new boron-containing antifungal agent, 5-fluoro-1,3-dihydro-1- hydroxy-2,1- benzoxaborole (AN2690), for the potential treatment of onychomycosis. J. Med. Chem. 49(15), 4447-4450 (2006
126. Seiradake E, Mao W, Hernandez V et al. Crystal structures of the human and fungal cytosolic Leucyl-tRNA synthetase editing domains: A structural basis for the rational design of antifungal benzoxaboroles. J. Mol Biol. 390(2), 196-207 (2009
127. Gupta AK, Simpson FC. New therapeutic options for onychomycosis. Expert Opin. Pharmacother. 13(8), 1131-1342 (2012
128. Hicks JW, Kyle CB, Vogels CM et al. Synthesis, characterization, and antifungal activity of boron-containing thiosemicarbazones. Chem. Biodivers. 5(11), 2415-2422 (2008
129. Drawz SM, Bonomo RA. Three decades of b-lactamase inhibitors. Clin. Microbiol. Rev. 23(1), 160-201 (2010
130. Bebrone C, Lassaux P, Vercheval L et al. Current challenges in antimicrobial chemotherapy: Focus on b-lactamase inhibition. Drugs 70(6), 651-679 (2010
131. Bush K, Jacoby GA. Updated functional classification of b-lactamases. Antimicrob. Agents Chemother. 54(3), 969-976 (2010
132. Morandi S, Morandi F, Caselli E, Shoichet BK, Prati F. Structure-based optimization of cephalothin-Tnalogue boronic acids as b-lactamase inhibitors. Bioorg. Med. Chem. 16(3), 1195-1205 (2008
133. Chen Y, Shoichet B, Bonnet R. Structure, function, and inhibition along the reaction coordinate of CTX-M b-lactamases. J. Am. Chem. Soc. 127(15), 5423-5434 (2005
134. Weston GS, Blázquez J, Baquero F, Shoichet BK. Structure-based enhancement of boronic acid-based inhibitors of AmpC b-lactamase. J. Med Chem. 41(23), 4577-4586 (1998
135. Bailey PJ, Cousins G, Snow GA, White AJ. Boron-containing antibacterial agents: Effects on growth and morphology of bacteria under various culture conditions. Antimicrob. Agents Chemother. 17(4), 549-553 (1980
136. Inglis SR, Zervosen A, Woon EC et al. Synthesis and evaluation of 3-(dihydroxyboryl)benzoic acids as D,D-carboxypeptidase R39 inhibitors. J. Med Chem. 52(19), 6097-6106 (2009
137. Zervosen A, Bouillez A, Herman A et al. Synthesis and evaluation of boronic acids as inhibitors of penicillin binding proteins of classes A, B and C. Bioorg. Med. Chem. 20(12), 3915-3924 (2012
138. Garcia-Soria G, Gonzalez-Galvez G, Argoud GM et al. The dipeptidyl peptidase-4 inhibitor PHX1149 improves blood glucose control in patients with Type 2 diabetes mellitus. Diabetes Obes. Metab. 10(4), 293-300 (2008
139. O'Farrell AM, van Vliet A, Abou Farha K et al. Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: Double-blind, placebo-controlled, single- And multiple-dose studies in healthy subjects. Clin. Ther. 29(8), 1692-1705 (2007
140. Abbenante G, Fairlie DP. Protease inhibitors in the clinic. Med. Chem. 1(1), 71-104 (2005
141. Smoum R, Rubinstein A, Dembitsky VM, Srebnik M. Boron containing compounds as protease inhibitors. Chem. Rev. 112(7), 4156-4220 (2012
142. Jacobs RT, Nare B, Wring SA et al. SCYX- 7158, an orally-Tctive benzoxaborole for the treatment of stage 2 human African trypanosomiasis. PLoS Negl. Trop. Dis. 5(6), e1151 (2011
143. Oliveira RA, Savegnago L, Jesse CR, Menezes PH, Molander GA, Nogueira CW. Toxicological investigation and antinociceptive property of potassium thiophen-3- trifluoroborate. Basic Clin. Pharmacol. Toxicol. 104(6), 448-454 (2009
144. Lecat-Guillet N, Ambroise Y. Discovery of aryltrifluoroborates as potent sodium/iodide symporter (NIS) inhibitors. ChemMedChem 3(8), 1207-1209 (2008
145. Zhong Y, Wu Y, Liu R et al. Novel retinoic acid receptor alpha agonists for treatment of kidney disease. PLoS ONE 6(11), e27945 (2011
146. Das BC, Tang XY, Evans T. Design and synthesis of boron containing potential pan-RAR inverse agonists. Tetrahedron Lett. 53(11), 1316-1318 (2012
147. Das BC, Tang XY, Sanyal S et al. Design and synthesis of 3,5-disubstituted-1,2,4-oxadiazole containing retinoids from a retinoic acid receptors agonist. Tetrahedron Lett. 52(19), 2433-2435 (2011
148. Das BC, McCartin K, Liu TC, Peterson RT, Evans T. A forward chemical screen in zebrafish identifies a retinoic acid derivative with novel specificity. PLoS ONE 5(4), e10004 (2010
149. Ciofani G. Potential applications of boron nitride nanotubes as drug delivery systems. Expert Opin. Drug Deliv. 7(8), 889-893 (2010
150. Chen X, Wu P, Rousseas M et al. Boron nitride nanotubes are noncytotoxic and can be functionalized for interaction with proteins and cells. J. Am. Chem. Soc. 131(3), 890-891 (2009